Nanobiotix to Present at H.C. Wainwright BioConnect Conference

Nanobiotix ( (NBTX) ) has shared an update.

On May 12, 2025, Nanobiotix announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ, scheduled for May 20, 2025. The company’s management, represented by Chief Financial & Business Officer Bart van Rhijn, will engage in fireside chats, which will be webcast live. This participation underscores Nanobiotix’s ongoing efforts to engage with investors and stakeholders, potentially enhancing its visibility and positioning within the biotechnology industry.

The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix faces substantial financial difficulties, including negative revenue, persistent losses, and a heavily leveraged balance sheet. While technical indicators suggest neutral to bearish momentum, the earnings call presented strategic collaborations and potential future milestones. However, the valuation remains unattractive due to negative earnings, and the overall outlook is constrained by ongoing financial challenges.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company, founded in 2003 and headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts. The company is pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases. It holds over 25 umbrella patents across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Average Trading Volume: 11,700

Technical Sentiment Signal: Sell

Current Market Cap: $163.2M

See more data about NBTX stock on TipRanks’ Stock Analysis page.